In 2012, the company reported net profit of RON32.2 million.
Zentiva Romania, which owns the former Sicomed plant in Bucharest, posted sales of RON291 million (EUR65.8 million) last year, up 20% from RON242.5 million in 2012.
The company’s total revenue increased 15% on the year to RON301.8 million, while overall expenditure was at RON248.8 million, up 12% from 2012.
In 2013, the company invested RON10.76 million in its production facilities and equipment.
According to the latest available data, French group Sanofi-Aventis owns 81.6% of Zentiva Romania’s shares.
On the Romanian market, the French drugmaker operates through two separate units: Sanofi-Aventis Romania and Zentiva Romania. Sanofi-Aventis is the leader of the domestic pharmaceutical market, with a share of 7.4%, according to market researcher Cegedim. (EUR1=RON4.4813)